Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042183 · ClinicalTrials.gov registry record · Phase 3
Lubiprostone in Children With Functional Constipation
A Phase 3 study, sponsored by Sucampo Pharma Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
NCT02042183 is a Phase 3 study that has completed, run by Sucampo Pharma Americas. The registered enrollment target is 606 participants.
The verdict
NCT02042183, a Phase 3 study, has completed, sponsored by Sucampo Pharma Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
Study Summary
Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.
Interventions
- DRUG Placebo
- DRUG Lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2016-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02042183
The ClinicalTrials.gov registry entry for NCT02042183 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02042183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02042183 about?
NCT02042183 is a clinical study titled "Lubiprostone in Children With Functional Constipation". Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.
What is the current status of trial NCT02042183?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2013-12-13. Estimated completion is 2016-07-27.
What interventions are being tested in trial NCT02042183?
The interventions under investigation include: Placebo (DRUG), Lubiprostone (DRUG).
Who is sponsoring clinical trial NCT02042183?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.